search
Back to results

The Baroloop Study

Primary Purpose

Hypertension

Status
Active
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
baroloop System
Sponsored by
neuroloop GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Aged 18 years or older and less than 80 years of age.
  2. Persistent office systolic blood pressure (SBP) ≥ 140 mm Hg and diastolic blood pressure (DBP) > 90 mm Hg on antihypertensive medicines on two visits separated by a minimum of four weeks.
  3. Mean 24-hour systolic ABPM ≥ 130 mm Hg and mean 24 hour diastolic ABPM ≥ 80 mm Hg conducted after direct observed therapy to confirm that antihypertensive medicines were taken as prescribed during the ABPM measurement.
  4. Stable drug regimen of 4 antihypertensive medicines consisting of a renin-angiotensin blocker(ACE) or Angiotensin II Receptor Blocker (ARBs), a calcium channel blocker (CCB), a diuretic and spironolactone for 4 weeks at treatment. If spironolactone is not tolerated, the regimen must include instead the addition of further diuretic therapy with either eplerenone, amiloride, higher-dose thiazide/thiazide-like diuretic or a loop diuretic, or the addition of bisoprolol or doxazosin. If none of these medicines are tolerated, then patients on a 3-drug regimen may be included.
  5. The Investigator has confirmed that the patient has already tried and/or is not suitable for treatment with currently CE-marked device-based therapies for resistant hypertension as an alternative to baroloop therapy.
  6. Willingness and ability to comply with follow-up requirements.
  7. Signed informed consent.

Exclusion Criteria:

  1. Any patient in whom access to the vagal nerve is limited by the size of the vagus (a size not compatible with the baroloop cuff).
  2. Any patient with a history of injury to the vagus nerve or its branches (e.g., the recurrent laryngeal nerve).
  3. Secondary causes of hypertension.
  4. Calculated eGFR < 30 mL/min/1.73m2.
  5. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1c > 10%).
  6. One or more episodes of orthostatic hypotension in the past year
  7. Requirement for chronic oxygen therapy or mechanical ventilation.
  8. Untreated (no CPAP therapy) sleep apnea (AHI > 15)
  9. Morbid obesity, defined as Body Mass Index >40 kg/m2 or arm circumference 46 cm.
  10. Pacemaker and/or implantable defibrillators.
  11. History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening.
  12. Symptomatic carotid artery disease or > 70% occlusion of either carotid artery; any carotid malformation or lesion, a carotid bruit or other abnormal carotid sound.
  13. Prior surgery, radiation therapy or scarring in the neck in the region of the carotid artery (e.g., patients with a tracheostomy, extensive thymectomy or thyroid surgery).
  14. Limited mobility of the neck secondary to vertebral disease or prior vertebral surgery, including patients who wear a cervical support.
  15. History of heart failure (NYHA class III-IV or ejection fraction < 30%), myocardial infarction, unstable angina, coronary bypass or coronary angioplasty during six (6) months prior to screening.
  16. Cardiac arrythmias (atrial fibrillation, atrial flutter, etc.) that require anticoagulation or interfere with a consistent measurement of blood pressure.
  17. Syncope in the last 6 months.
  18. History of bleeding disorders, thrombocytopenia, hemophilia or significant anemia (hemoglobin (Hgb) < 10 gm/dl).
  19. Current anticoagulation therapy (excluding antiplatelet therapy with aspirin as a sole therapy).
  20. Works night shifts.
  21. History of unresolved drug or alcohol use.
  22. Active treatment of a psychiatric ailment.
  23. Life expectancy of less than 12 months due to other disease.
  24. Subject has a condition that, in the opinion of the investigator, precludes participation, including willingness to comply, with all follow-up procedures.
  25. Participation in another clinical study for which follow-up is currently on-going.
  26. Women who are of child-bearing age or who have the potential to become pregnant
  27. Resting heart rate of <40 beats/min for patients on beta blockers or <60 beats/min for all other patients, confirmed at both baseline visits.
  28. Baroreflex failure or autonomic neuropathy
  29. Symptomatic, uncontrolled bradyarrhythmias
  30. Atrioventricular block of any grade
  31. Patients who are treated with Pacemaker and/or implantable defibrillators
  32. Presence of a vagus stimulator
  33. Patients who expect to require magnetic resonance imaging (MRI) of the cervical area
  34. Occupational exposure to high levels of non-ionizing radiation that may interfere with therapy
  35. Patients with a limited ability to read, understand and execute adjustment procedures (for example, persons suffering from dementia).
  36. Likely exposure to diathermy.

Sites / Locations

  • UMC Utrecht

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Investigational Device

Arm Description

Subjects implanted with the baroloop device

Outcomes

Primary Outcome Measures

Composite Major Adverse Event (MAE) Rate
The MAE consists of all causes of death, hospitalization for hypertensive crisis post-titration, and any device or procedure-related serious adverse events
Feasibility - device placement and vagal nerve stimulation
Feasibility is defined as the ability of the baroloop System to be placed around a vagal nerve and to stimulate the nerve

Secondary Outcome Measures

Change in blood pressure
Change in blood pressure recorded during intraoperative stimulation
Change in 24-hour ABPM
Mean change of 24-hour ambulatory systolic and diastolic blood pressure post-treatment versus baseline
Composite MAE rate
he MAE consists of all causes of death, hospitalization for hypertensive crisis post-titration, and any device or procedure-related serious adverse events
Change in Office Blood Pressure
Mean change in office systolic and diastolic blood pressure
Change in antihypertensive drugs/dosages
Changes in antihypertensive drugs/dosages post-implantation as analyzed by Daily Defined Dosages (WHO Definition) and total medications
Quality of Life Evaluation - Short Form (36) Health Survey
Quality of Life as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Full Information

First Posted
July 20, 2021
Last Updated
August 20, 2023
Sponsor
neuroloop GmbH
Collaborators
MAXIS GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT04981470
Brief Title
The Baroloop Study
Official Title
A First in Human Study of Feasibility of Baroloop: The Baroloop Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 13, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
neuroloop GmbH
Collaborators
MAXIS GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The baroloop Study is a non-randomized, prospective, single-arm, multi center First in Human (FIH) study with the primary objective being the assessment of the safety and feasibility of using the baroloop System in subjects with uncontrollable hypertension. The secondary objective is to document the effect of the baroloop device on the blood pressure and quality of life in subjects with hypertension. Up to 10 subjects will be enrolled in up to 3 sites in Europe.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Investigational Device
Arm Type
Experimental
Arm Description
Subjects implanted with the baroloop device
Intervention Type
Device
Intervention Name(s)
baroloop System
Intervention Description
vagal nerve stimulation
Primary Outcome Measure Information:
Title
Composite Major Adverse Event (MAE) Rate
Description
The MAE consists of all causes of death, hospitalization for hypertensive crisis post-titration, and any device or procedure-related serious adverse events
Time Frame
at 6 months post-treatment
Title
Feasibility - device placement and vagal nerve stimulation
Description
Feasibility is defined as the ability of the baroloop System to be placed around a vagal nerve and to stimulate the nerve
Time Frame
Day 14 or Day 21 post-implantation
Secondary Outcome Measure Information:
Title
Change in blood pressure
Description
Change in blood pressure recorded during intraoperative stimulation
Time Frame
at the time of implantation
Title
Change in 24-hour ABPM
Description
Mean change of 24-hour ambulatory systolic and diastolic blood pressure post-treatment versus baseline
Time Frame
1, 3, 6, 12, 18 and 24 months
Title
Composite MAE rate
Description
he MAE consists of all causes of death, hospitalization for hypertensive crisis post-titration, and any device or procedure-related serious adverse events
Time Frame
1, 3, 12, 18 and 24 months
Title
Change in Office Blood Pressure
Description
Mean change in office systolic and diastolic blood pressure
Time Frame
1, 3, 6, 12, 18 and 24 months
Title
Change in antihypertensive drugs/dosages
Description
Changes in antihypertensive drugs/dosages post-implantation as analyzed by Daily Defined Dosages (WHO Definition) and total medications
Time Frame
1, 3, 6, 12, 18 and 24 months
Title
Quality of Life Evaluation - Short Form (36) Health Survey
Description
Quality of Life as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time Frame
Baseline, 1, 3, 6, 12, 18 and 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18 years or older and less than 80 years of age. Persistent office systolic blood pressure (SBP) ≥ 140 mm Hg and diastolic blood pressure (DBP) > 90 mm Hg on antihypertensive medicines on two visits separated by a minimum of four weeks. Mean 24-hour systolic ABPM ≥ 130 mm Hg and mean 24 hour diastolic ABPM ≥ 80 mm Hg conducted after direct observed therapy to confirm that antihypertensive medicines were taken as prescribed during the ABPM measurement. Stable drug regimen of 4 antihypertensive medicines consisting of a renin-angiotensin blocker(ACE) or Angiotensin II Receptor Blocker (ARBs), a calcium channel blocker (CCB), a diuretic and spironolactone for 4 weeks at treatment. If spironolactone is not tolerated, the regimen must include instead the addition of further diuretic therapy with either eplerenone, amiloride, higher-dose thiazide/thiazide-like diuretic or a loop diuretic, or the addition of bisoprolol or doxazosin. If none of these medicines are tolerated, then patients on a 3-drug regimen may be included. The Investigator has confirmed that the patient has already tried and/or is not suitable for treatment with currently CE-marked device-based therapies for resistant hypertension as an alternative to baroloop therapy. Willingness and ability to comply with follow-up requirements. Signed informed consent. Exclusion Criteria: Any patient in whom access to the vagal nerve is limited by the size of the vagus (a size not compatible with the baroloop cuff). Any patient with a history of injury to the vagus nerve or its branches (e.g., the recurrent laryngeal nerve). Secondary causes of hypertension. Calculated eGFR < 30 mL/min/1.73m2. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1c > 10%). One or more episodes of orthostatic hypotension in the past year Requirement for chronic oxygen therapy or mechanical ventilation. Untreated (no CPAP therapy) sleep apnea (AHI > 15) Morbid obesity, defined as Body Mass Index >40 kg/m2 or arm circumference 46 cm. Pacemaker and/or implantable defibrillators. History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening. Symptomatic carotid artery disease or > 70% occlusion of either carotid artery; any carotid malformation or lesion, a carotid bruit or other abnormal carotid sound. Prior surgery, radiation therapy or scarring in the neck in the region of the carotid artery (e.g., patients with a tracheostomy, extensive thymectomy or thyroid surgery). Limited mobility of the neck secondary to vertebral disease or prior vertebral surgery, including patients who wear a cervical support. History of heart failure (NYHA class III-IV or ejection fraction < 30%), myocardial infarction, unstable angina, coronary bypass or coronary angioplasty during six (6) months prior to screening. Cardiac arrythmias (atrial fibrillation, atrial flutter, etc.) that require anticoagulation or interfere with a consistent measurement of blood pressure. Syncope in the last 6 months. History of bleeding disorders, thrombocytopenia, hemophilia or significant anemia (hemoglobin (Hgb) < 10 gm/dl). Current anticoagulation therapy (excluding antiplatelet therapy with aspirin as a sole therapy). Works night shifts. History of unresolved drug or alcohol use. Active treatment of a psychiatric ailment. Life expectancy of less than 12 months due to other disease. Subject has a condition that, in the opinion of the investigator, precludes participation, including willingness to comply, with all follow-up procedures. Participation in another clinical study for which follow-up is currently on-going. Women who are of child-bearing age or who have the potential to become pregnant Resting heart rate of <40 beats/min for patients on beta blockers or <60 beats/min for all other patients, confirmed at both baseline visits. Baroreflex failure or autonomic neuropathy Symptomatic, uncontrolled bradyarrhythmias Atrioventricular block of any grade Patients who are treated with Pacemaker and/or implantable defibrillators Presence of a vagus stimulator Patients who expect to require magnetic resonance imaging (MRI) of the cervical area Occupational exposure to high levels of non-ionizing radiation that may interfere with therapy Patients with a limited ability to read, understand and execute adjustment procedures (for example, persons suffering from dementia). Likely exposure to diathermy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wilko Spiering
Organizational Affiliation
UMC Utrecht
Official's Role
Principal Investigator
Facility Information:
Facility Name
UMC Utrecht
City
Utrecht
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

The Baroloop Study

We'll reach out to this number within 24 hrs